Dermorphin
- Category
- Muscle & Performance
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A frog-skin opioid peptide binding mu-opioid receptors at roughly 30 to 40 times morphine potency. Human evidence is limited to one small 1985 trial; longer-term safety data come mostly from animal and veterinary studies. It requires invasive spinal delivery to act centrally, carries risks of respiratory depression and dependence, and is already misused as a doping agent in horse racing. Not an approved human drug, with no legitimate research-grade supply.
Read Full recordStudied uses & evidence
Studied uses(6)
Potent analgesia via mu-opioid receptor agonism
MediumAnimal assays found approximately 39–40 times morphine's potency; this is not a measured human potency ratio.
Prolonged postoperative pain relief (mean 43 hours from single intrathecal injection vs 34 hours for morphine)
MediumSingle 1985 randomized trial, never replicated, found significantly longer relief than morphine.
Reduced need for supplementary analgesics (only 22% of patients vs 58% for morphine, 88% for placebo)
MediumSame 1985 trial; comparator was active pentazocine, not an inert placebo, never replicated.
Evidence limits
- Evidence Level
- Limited
A randomized postoperative clinical trial with active comparators (1985) demonstrated superior postoperative analgesia via intrathecal dermorphin versus intrathecal morphine and intramuscular pentazocine. Dermorphin provided 43-hour mean analgesia duration with 80% of patients needing no additional pain medication. No subsequent clinical trials have been conducted. Extensive preclinical data in rodents and horses confirm potent mu-opioid agonism. The 1985 clinical paper has received only ~15 citations, none from clinical researchers, representing a significant gap in translational development.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Opioid addiction or dependence
AbsoluteExtremely potent mu-opioid agonist (30-40x morphine). High addiction potential.
Respiratory depression risk
AbsolutePotent opioid activity can cause life-threatening respiratory depression.
Concurrent opioid or sedative use
AbsoluteAdditive CNS depression risk. Can be fatal in combination.
Risk summary(10)
Risks = level of concern: High · Moderate · Low · Theoretical
Nausea and vomiting — Reported in up to 50% of patients in open-label studies; reducible to <20% with domperidone pretreatment
HighUrinary retention — 26% incidence in the 1985 clinical trial (comparable to morphine at 30%)
ModerateRespiratory depression — Expected class effect of potent mu-opioid agonists; not specifically quantified for dermorphin in humans but a theoretical concern given extreme potency
ModerateTolerance and physical dependence — Demonstrated in animal models, though less pronounced than with morphine (65% vs 10% maintaining analgesia at 4 days continuous infusion)
ModerateExcitation and cardiovascular effects — Intravenous administration in horses caused acute excitation and increased heart rate (resolved within 5 minutes)
LowCannot cross blood-brain barrier — Requires invasive intrathecal or intracerebroventricular administration, carrying inherent procedural risks (infection, headache, nerve damage)
HighEndocrine disruption — Stimulates thyrotropin (TSH) secretion and decreases luteinizing hormone (LH) levels in humans
ModerateAbuse potential — High potency mu-opioid agonist with significant abuse liability; already misused in horse racing
ModerateLack of safety data — Human evidence includes a 150-patient postoperative randomized trial and small endocrine studies; long-term safety remains unknown.
HighNaloxone reversal eliminates analgesia — While naloxone reverses adverse effects, it simultaneously abolishes all analgesic benefit
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.